Search

Summary: Management of classical Hodgkin lymphoma in older patients is challenging due to poor tolerance of the chemotherapy regimens used in younger patients. We modified the BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone), whereby bleomycin and etoposide were removed and cyclophosphamide dose was reduced, for older patients with co‐morbidities. Here we present data from the first 41 patients treated with 'ACOPP' across 3 centres, demonstrating that it can be delivered, with a favourable toxicity profile (TRM 2%) and promising efficacy (2‐year PFS and OS, 73% (95% CI: 52–94) and 93% (95% CI: 80–100) respectively). [ABSTRACT FROM AUTHOR]

The article discusses a study which identified a series of 5 consecutive patients presenting with hypomegakaryocytic thrombocytopenia (HMT) and low-to-intermediate risk myelodysplastic syndrome (MDS). Topics covered include the clinical characteristics of patients, the role of immune dysregulation in the pathophysiology of MDS, and the response of patients to ciclosporin (CsA) therapy.

Central nervous system relapse of primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma There was no evidence of systemic disease on computed tomography (CT) imaging and therefore a diagnosis of primary cutaneous CD8 SP + sp aggressive epidermotropic cytotoxic T-cell lymphoma was made. Cutaneous CD8 SP + sp T-cell lymphoma is a rare and aggressive lymphoma. [Extracted from the article]